AKT1 and breast carcinoma: Targeting oncogenic signaling pathways in TNBC, such as the PI3K-AKT, MAPK, and androgen receptor (AR) pathways, has been approved for breast cancer treatment and is under clinical development.[99] The Hippo-YAP, AMP-activated protein kinase (AMPK), HIF1α, and mechanistic target of rapamycin complex 1 (mTORC1) signaling pathways regulate ferroptosis through various mechanisms.[86,100] It is noteworthy that different organelles, such as the mitochondria and the endoplasmic reticulum, regulate ferroptosis in an organelle-dependent manner.